Gain Therapeutics Files 8-K
Ticker: GANX · Form: 8-K · Filed: Apr 10, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Reporting
TL;DR
Gain Therapeutics filed a routine 8-K on 4/10/25, no major news.
AI Summary
Gain Therapeutics, Inc. filed an 8-K on April 10, 2025, reporting on other events and financial statements. The filing does not contain specific details about new material events, significant financial changes, or executive actions beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates that Gain Therapeutics, Inc. is adhering to its reporting obligations with the SEC, but it does not disclose any new material information that would immediately impact the company's stock or operations.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain any new material information, significant financial events, or strategic changes that would indicate increased risk.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- 001-40237 (company_id) — Commission File Number
- 85-1726410 (ein) — I.R.S. Employer Identification No.
- Bethesda, Maryland (location) — Principal executive offices
- April 10, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Gain Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of April 10, 2025.
What is the Commission File Number for Gain Therapeutics, Inc.?
The Commission File Number for Gain Therapeutics, Inc. is 001-40237.
Where are the principal executive offices of Gain Therapeutics, Inc. located?
The principal executive offices of Gain Therapeutics, Inc. are located at 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is April 10, 2025.
Does this 8-K filing disclose any specific new material events or financial updates?
Based on the provided text, this 8-K filing is a standard report and does not explicitly disclose any specific new material events or detailed financial updates beyond the categorization of items.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 10, 2025 regarding Gain Therapeutics, Inc. (GANX).